Sage Therapeutics Inc. buy Royal Bank of Canada
Start price
13.03.23
/
50%
€42.33
Target price
13.03.24
€56.02
Performance (%)
-56.77%
End price
14.03.24
€18.30
Summary
This prediction ended on 14.03.24 with a price of €18.30. The BUY prediction by Royal_Bank_of_Canada for Sage Therapeutics Inc. performed very badly with a performance of -56.77%. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Sage Therapeutics Inc. | - | - | - | - |
| iShares Core DAX® | -0,48 % | -12,06 % | -2,95 % | 43,35 % |
| iShares Nasdaq 100 | -3,38 % | -5,13 % | 9,58 % | 72,42 % |
| iShares Nikkei 225® | -0,14 % | -12,63 % | 20,32 % | 43,44 % |
| iShares S&P 500 | -2,27 % | -5,05 % | 5,80 % | 54,98 % |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Sage Therapeutics Inc. diskutieren
Sage Therapeutics, Inc. (NASDAQ: SAGE) was upgraded by analysts at Royal Bank of Canada from a "sector perform" rating to an "outperform" rating. They now have a $60.00 price target on the stock, up previously from $40.00.
Ratings data for SAGE provided by MarketBeat
In the thread Trading Sage Therapeutics Inc.
Die von Royal_Bank_of_Canada gewählte maximale Laufzeit wurde überschritten